Tuesday, June 14, 2016 11:08:23 AM
Those participating in ELTP’s Conference Call Q&A session are limited to asking one question following ELTP management’s opening statements.
To make the most of this Q&A opportunity, suggest that we come up with a list to share of top questions to ask:
[copy/past list and add your question at the bottom]
1. ELI-200/SequestOx
A. FDA's Advisory Committee review of Pfizer's ALO 02/Troxyca ER determined that "Oxycodone can be selectively extracted from intact pellets
by a number of straightforward techniques and certain common solvents appear to be capable of removing naltrexone selectively from crushed pellets."
How do ELI-200/SequestOx's results compare if subjected to the same criteria?
B. Is a media/PR campaign planned if ELI-200/SequestOx receives FDA's approval and becomes the first and only IR ADT with label?
2. ELI-201.
A. Progress/status update.
B. There are multiple viable pathways to obtaining approval for ELI-201. Is it accurate to conclude that if anything other than ALO 02/Troxyca ER is
used as the direct comparator, then Phase 3 would be required?
3. Progress/status update on ELI-202.
4. Has Elite entertained the sale of its generic line of business since it would provide capital needed to push the balance of the portfolio through FDA submission?
5. How much does a fluid bed dryer cost? Does Elite have the room to add a 2nd 1000 Kilo or will they need a new
manufacturing site and/or partner?
6. When can we expect the shareholder's meeting?
7. Tell about the connections with the Chinese - and what future developments are you expecting.
"Life is tough, but it's tougher if you're stupid"... John Wayne (Sgt. Stryker - Sands of Iwo Jima)
Recent ELTP News
- Form 8-K - Current report • Edgar (US Regulatory) • 08/27/2024 08:30:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 09:16:11 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 08:05:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 08:07:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2024 08:30:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 09:55:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/29/2023 07:21:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/26/2023 09:20:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/12/2023 09:20:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/28/2023 12:05:38 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/27/2023 11:58:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/27/2023 11:50:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration with ZenaDrone • InvestorsHub NewsWire • 11/16/2023 12:32:07 PM
FEATURED SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service To Enhance Natural Rubber Industry's Ability to Report on Sustainable and Ethical Supply Chains • Oct 3, 2024 7:00 AM
Basanite, Inc. Appoints Ali Manav as Interim Chief Executive Officer • BASA • Oct 3, 2024 9:15 AM
Integrated Ventures Announces Launch of MedWell Facilities, LLC and Lease Agreement with Giant Fitness Clubs • INTV • Oct 3, 2024 8:45 AM
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More • NVS • Oct 3, 2024 8:45 AM
Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition • PFE • Oct 2, 2024 9:00 AM
Unitronix Corp Unveils Cryptocurrency Investment Portfolio Strategy • UTRX • Oct 2, 2024 8:40 AM